Clinical studies highlight that Eli Lilly (LLY, Financial) and Novo Nordisk's (NVO) weight loss drugs result in significant lean body mass reduction, with 25% and 40% of weight loss attributed to muscle loss, respectively. In response, Regeneron (REGN) is researching a new drug aimed at mitigating muscle loss caused by weight loss medications. While drugs like Ozempic and Wegovy have spurred a "gold rush" in the pharmaceutical industry, George Yancopoulos, co-founder of Regeneron, warns of potential muscle ...

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists Elevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets Licensed Product / Nation Patent Application Serial No. Title: Pharmaceutical composition for alleviation, treatment, and prevention of sarcopenia containing microorganism transformed with cell surface display ...

Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, announces the release of its latest innovation, "TRIM," a compounded, oral dissolvable Tirzepatide tablet. Available for purchase at $399 per month, this new product offers patients an advanced and convenient alternative to injectable therapies. Tirzepatide, a dual GIP ...

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists Elevai Biosciences patent portfolio now includes 4 patent applications and 5 issued patents that provide adequate protection in focus markets Licensed Product / Nation Patent Application Serial No. Title: Pharmaceutical composition for alleviation, treatment, and prevention of sarcopenia containing microorganism transformed with cell surface display ...

Gain access to all of the market research and financial analytics used in the preparation of this article plus exclusive content and pharma, healthcare and biotech investment recommendations and research / analytics by subscribing to my channel, Haggerston BioHealth. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts for all the Big Pharmas, forecasting, integrated financial statements, ...

JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera's proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonist GLP-1/gluc ...

SAFETY HARBOR, Fla., Sept. 24, 2024 /PRNewswire/ --- Integrated Ventures Inc. ("Company", "OTCQB: INTV") is pleased to announce that its newly launched subsidiary, MedWell USA, LLC has signed a strategic and valuable Management Services Organization ("MSO") agreement with FDA licensed manufacturer of pharmaceutical products. This agreement enables MedWell USA to act as a Procurement Agent for Semaglutide, a leading pharmaceutical product in the weight management sector. MedWell USA will leverage various mar ...

Educational panel available for free via the Life Time App 6:00-7:30 p.m. CT CHANHASSEN, Minn., Sept. 23, 2024 /PRNewswire/ -- With interest in and demand for GLP-1 peptides continuing to explode, Life Time (NYSE: LTH) announced today that it will host a complimentary, informational livestreamed panel on September 25. The event is available to everyone via the complimentary Life Time App, and features insights from Life Time Chief Science Officer James LaValle, MIORA Medical Director Dr. Gregory Pippert and ...

Terns has a modest market cap of less than $800 million, and its possible upside could be massive. Goldman Sachs projects that the anti-obesity market will be worth as much as $100 billion by the end of the decade. It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The best-selling glucagon-like peptide-1 (GLP-1) weight-loss treatments today are injections, but companies are working on pills which could be more attractive to patients, es ...

J Studios Introduction The telehealth company Hims & Hers (NYSE:HIMS) has seen its stock price range from under $6 to over $25 during the last 52 weeks. Since the stock price peaked in June, the stock has almost been cut in half. Back in May Hims surprised the market by announcing its affordable GLP-1 offering which immediately sent the stock soaring. However, recent news regarding Hims ability to continue with its GLP-1 offering beyond the temporary shortage has led to uncertainty around the stock. As of w ...